Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: 4 - What They Never Told You

The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

SIGA Technologies Announces $13M Worth Order For Its Monkeypox Treatment

SIGA Technologies Inc (NASDAQ:SIGA) has announced approximately $13 million in procurement orders for oral TPOXX (tecovirimat) The order includes $11 million for initial procaurement from two new international jurisdictions and an approximate $2 million order from a country in the Asia Pacific region with an established contract for oral TPOXX. "We expect a…

Benzinga

Nextleaf To Launch THC-O As An Excise Tax-Free Alternative To Delta-9-THC

Nextleaf Solutions Ltd.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

MDMA trials under review in Canada over alleged abuse of study participants

Health Canada confirms reviews into trials following complaint of ‘alleged investigator misconduct’

The Guardian - US

Canadian Special Access Program Further Authorizes Novel Psychedelic Drugs For Emergency Treatments

For those unaware, Canada provides a legal way for patients presenting unresolved mental health issues to receive psychedelic-assisted treatment.

Benzinga

Canada Approves Amylyx's ALS Drug; FDA To Consider Approval In September

The Canadian government has given its approval to AMX0035, a new drug from Cambridge, Massachusetts-based Amylyx Pharmaceuticals Inc.

Benzinga

Tetra Bio-Pharma Opens New Subsidiary In Australia And Provides Regulatory Update

Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB: TBPMF) (FRA:JAM1) launched new wholly owned subsidiary 'Tetra Bio-Pharma Australia Pty Ltd', an Australian-based research company focused on the execution of clinical trials in Australia.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Numinus' Ongoing Collaboration With Health Canada Spurs Mindspace Clinic Approval In Quebec

A longstanding commitment of Numinus Wellness Inc. (OTC: NUMIF) to collaborate with Health Canada to help shape protocols for the Special Access Program appears to be paying dividends.

Benzinga

EDSA: Enrollment of Phase 2b Trial of EB01 to Complete in 4Q22…

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT

Benzinga

Isracann Biosciences' Subsidiary Praesidio Health Submits NPNs To Health Canada

Praesidio Health, a wholly-owned subsidiary of Isracann Biosciences Inc. (OTCPK:ISCNF) (CSE:IPOT) (XFRA:A2PT0E), has completed the natural product number (NPN) submissions to Health Canada for its first formulations.

Benzinga

Numinus Granted Canada's Special Access Program For Magic Mushrooms To Treat Life-Threatening Conditions

Numinus Wellness Inc (OTCQB: NUMIF) has been approved to use psilocybin-assisted therapy through Health Canada’s Special Access Program (SAP), marking the first instance in which Numinus will provide this treatment outside of a clinical trial.

Benzinga

Red Light Holland Sends Magic Mushrooms Into Canada To Be Used As Pharmaceutical Ingredients

Red Light Holland (OTCPK:TRUFF) has announced the successful export of psilocybin truffles to its partner in Canada, CCrest Laboratories, through a permit given by Health Canada.

Benzinga

Democrats call on FDA to remove ‘antiquated discriminatory’ limits on gay, bisexual men donating blood amid Canadian decision

Val Demings and Mark Takano tell The Independent the US should also ‘follow science’

The Independent UK

Cannabis Movers & Shakers: Blinc Group, HEXO, Grower's Ally, Halo Collective

The Blinc Group Names New COO The Blinc Group, Inc., a regulatory-focused designer, and provider of premium customized vaporizer technologies, has tapped cannabis industry veteran Pete Sahani to serve as its new chief operating officer.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Hexo Makes Leadership Changes, Appoints New CEO & CFO

HEXO Corp (NASDAQ: HEXO) (TSX:HEXO) announced that Charlie Bowman has been appointed the company’s acting president and CEO.

The Independent UK

Canada to lift restrictions on gay men donating blood

Health Canada has lifted restrictions on gay men donating blood, a move Prime Minister Justin Trudeau says is “good news for all Canadians” but took too long

StockNews.com

5 Resilient Stocks to Buy for a Market Downturn

Yesterday, the broad market indices closed in negative territory on interest-rate-increase concerns. Goldman Sachs has predicted that the S&P might tumble to 3,600 this year if recessionary pressure persists. Non-cyclical stocks usually perform well during economic downturns. So, we believe Cardinal Health (CAH), Brookfield Infrastructure Corp. (BIPC), Smith & Nephew…

Benzinga

Sproutly Forms Joint Venture With Kingston Cannabis, Here Is Why

Sproutly Canada, Inc. (OTCQB: SRUTF) (CSE:SPR) (FSE: 38G), is expanding its commercial relationship with Kingston Cannabis Inc., a Health Canada Licensed processor.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Health Canada Approves Grapefruit USA's Hourglass Time Release THC+CBD Delivery Cream For Sale

Grapefruit USA, Inc. (OTCQB: GPFT), announced that its notice of new cannabis product (“NNCP”), filed with Health Canada on Jan.

Benzinga

Delic Labs Receives Exemption To Conduct Research On MDMA, LSD And Other Psychedelic Compounds

Delic Labs subsidiary of Delic Holdings Corp (OTCQB:DELCF) (CSE:DELC) (FRA: 6X0), received a Health Canada 56 research exemption that will allow scientists to conduct research and perform tests on a number of compounds outside of psychedelic mushrooms, including MDMA, LSD, DMT, mescaline and 2C-B. Additionally, Delic Labs has received a…

Benzinga

Adastra Submits Medical Sales License Application And Engages IR Labs To Provide Investor Relations Services

Adastra Holdings Ltd. (OTCPK:XTXXF) (CSE:XTRX) (FRA:D2EP) submitted medical sales license application to Health Canada on April 1, 2022. A medical sales license would permit Adastra to perform the following activities:

Benzinga

Nova Mentis Is Looking To Treat Autism With Psilocybin

Nova Mentis Life Science Corp. (OTCQB:NMLSF) and the private college Toronto Institute of Pharmaceutical Technology have signed a contract for the production of psilocybin capsules. The company will supply the microdose capsules for a Phase 2A fragile X syndrome (FXS) clinical study. FXS, also known as Martin-Bell syndrome, is one…

Benzinga

Canadian Cannabis Producers Are Financially Squeezed: Unpaid Marijuana Fees Grow 10X YoY To CA$914K

Has competition in the Canadian cannabis market finally reached its climax?

Benzinga

Hempsana Teams Up With GAMA To Launch New Cannabis Product Offerings And Brands

Hempsana Holdings Ltd. has entered into a contract manufacturing agreement with GAMA Corp to co-manufacture and distribute new products and brands from the United States to the Canadian and International Markets for both recreational and medicinal use.

Benzinga

Adastra Holdings Approved For Dealer's License For Psilocybin, Psilocin, MDMA, DMT, 5-MeO-DMT & LSD

Adastra Holdings Ltd. (OTCPK: XTXXF) (CSE: XTRX) (FRA: D2EP) recently completed the submission of its application for a controlled drugs and substances dealer's license. What Does It Mean?

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

European Medicines Agency

76 stories

Vertex Pharmaceuticals Incorporated

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.